Study doubts efficacy of whooping cough vaccine
A new study has raised questions on the long-term efficacy of Whooping cough vaccine given to infants.
Published in Pediatrics
journal on June 10, it suggests the efficacy of the vaccine, commonly known as DTaP, could be reducing or failing to achieve desirable results as the child grows.
The study found that the risk of pertussis infection was 13 times higher among children who are not vaccinated and 1.9 times higher on children who were under-vaccinated compared to fully vaccinated ones.
Further, the findings also showed that among children who were appropriately vaccinated, the risk of pertussis increased as they got further away from their last DTaP dose.
“This suggests that the vaccine's effectiveness wanes over time,” said Ousseny Zerbo, a staff scientist at Vaccine Study Centre in Northern California.
The study incorporated 469,982 children aged between three and 11 years from Northern California in the United States, where 738 cases of pertussis were identified.
For More of This and Other Stories, Grab Your Copy of the Standard Newspaper.
Of the 738 cases, 99 were not vaccinated, 36 were under-vaccinated, 515 were fully vaccinated and 88 were fully vaccinated plus one dose.
We are undertaking a survey to help us improve our content for you. This will only take 1 minute of your time, please give us your feedback by clicking HERE. All responses will be confidential.
Whooping cough vaccineWhooping coughDTaP